Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEANIC STROKE phase 3 trial of asundexian after non-cardioembolic ischemic stroke or high-risk TIA
MOH_2023-01-24_012195Phase 3Completed
- Sponsor
- Bayer
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke and transient ischaemic attack (TIA) comparing Asundexian plus background antiplatelet therapy with Placebo plus background antiplatelet therapy (2 arms). Started Jan 2023; status: completed.
02
Drugs
asundexian
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on MOH_2023-01-24_012195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-01-24_012195.